Home / Companies / News / Covid-19 crisis: Cipla launches generic remdesivir under brand name Cipremi

Covid-19 crisis: Cipla launches generic remdesivir under brand name Cipremi

The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of Covid-19 patients

food, demand, sales, FMCG, consumer, customers, coronavirus

Premium

In May, Gilead Sciences Inc extended a voluntary non-exclusive license to Cipla to manufacture and market generic version of remedisvir called Cipremi

Press Trust of India

2 min read Last Updated : Jun 21 2020 | 10:36 PM IST

Homegrown pharma major Cipla Ltd announced the launch of its generic version of remdesivir, which has been authorised for emergency use in treatment of Covid-19 patients by the USFDA, under its brand name Cipremi.

The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of Covid-19 patients.

Remdesivir is the only USFDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed Covid-19 infection.

In May, Gilead Sciences Inc extended a voluntary non-exclusive license to Cipla to manufacture and market generic version

Topics : Coronavirus Lockdown USFDA Coronavirus Vaccine Cipla

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in